The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
In this video, Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the association between functionally high-risk disease and inferior outcomes after CAR T-cell therapy for relapsed/refractory (R/R) multiple myeloma (MM), highlighting that while CAR T-cell therapy can overcome the negative prognostic impact of functionally high-risk disease when given in earlier lines of treatment, it may not do so as a late-line therapy. As a result of this, Dr Hashmi recommends that patients with functionally high-risk disease who progress within 24 months of their frontline therapy should be considered for CAR-T at first relapse. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
